Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 3:16 PM ET

Healthcare Providers and Services

Company Overview of Profarma Distribuidora de Produtos Farmacêuticos S.A.

Company Overview

Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution, wholesale, and retail of pharmaceutical and hospital products in Brazil. The company operates through Pharmaceutical Distribution, Specialties, and Retail divisions. It provides medicines, personal care, beauty, and dermatological products; and toiletries, vaccines, prostheses, and hormones in the South, Southeast, Northeast, and Center-West regions of Brazil through 12 distribution centers. The company also operates approximately 123 stores in the state of Rio de Janeiro. In addition, it provides information technology, cargo and transportation planning and control, and sales ...

Avenida das Américas, 500

bloco 12, sala 106

Rio de Janeiro, RJ 22640-100

Brazil

Founded in 1961

Key Executives for Profarma Distribuidora de Produtos Farmacêuticos S.A.

Profarma Distribuidora de Produtos Farmacêuticos S.A. does not have any Key Executives recorded.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Key Developments

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, the consolidated company reported net revenues of BRL 823.707 million compared with BRL 842.608 million for the same period a year ago. EBIT was BRL 9.4 million compared with BRL 8.6 million for the same period a year ago. EBITDA was BRL 13.5 million compared with BRL 11.9 million for the same period a year ago. Net loss was BRL 7.6 million or BRL 0.2 per batch of 1,000 shares compared with BRL 13.5 million or BRL 0.4 per batch of 1,000 shares for the same period a year ago. Net debt was BRL 205.1 million compared with BRL 412.0 million for the same period a year ago. Net cash from operating activities was BRL 32.9 million compared with BRL 81.0 million for the same period a year ago. Additions to fixed assets was BRL 8.642 million compared with BRL 3.899 million for the same period a year ago. Additions to intangible assets were BRL 0.208 million compared with BRL 0.40 million a year ago. Quarter-over-quarter, gross revenue dropped by 5.7%, mainly due to a 5.7% drop in the Pharmaceutical Distribution division's sales. Adjusted EBITDA came to BRL 13.5 million in first quarter of 2015 (1.6% margin), up 13.2% from first quarter of 2014, when it amounted to BRL 11.9 million (1.4% margin) despite the split-up of the Specialties division­which added BRL 2.1 million to EBITDA in first quarter of 2014 in comparison to a negative BRL 0.1 million booked under equity income (losses) in first quarter of 2015. For the quarter, the parent company reported net operating revenues of BRL 788.945 million compared with BRL 735.492 million for the same period a year ago. Operating loss was BRL 9.811 million compared with BRL 14.763 million for the same period a year ago. Net loss was BRL 7.636 million or BRL 1848 per batch of 1,000 shares compared with BRL 13.536 million or BRL 408 per batch of 1,000 shares for the same period a year ago. Net cash from operating activities was BRL 37.654 million compared with BRL 100.489 million for the same period a year ago. Additions to fixed assets were BRL 5.656 million compared with BRL 1.320 million for the same period a year ago. EBITDA amounted to BRL 15.4 million (2.0% margin) in first quarter of 2015, rising by 19.4% and 20.8% year-over-year and quarter-over-quarter respectively. This increase mainly resulted from a 6.6% increase in sales in comparison to first quarter of 2014 and a fall in operating (SGA) expenses in absolute amounts (BRL 6.7 million) quarter-over-quarter.

Profarma Distribuidora de Produtos Farmacêuticos S.A. to Report Q1, 2015 Results on May 11, 2015

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced that they will report Q1, 2015 results on May 11, 2015

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Consolidated and Parent Earnings Results for Fourth Quarter and Full Year Ended December 31, 2014

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced consolidated and parent earnings results for fourth quarter and full year ended December 31, 2014. For the quarter, on consolidated basis, the company reported net operating revenue of BRL 872,688,000, operating loss prior to financial results of BRL 2,982,000, operating loss of BRL 24,611,000, net loss of BRL 20,156,000 or BRL 486 per batch of one thousand shares, cash used in operating activities of BRL 14,517,000, additions to fixed assets of BRL 8,481,000, additions to intangible assets of BRL 2,586,000 compared to the net operating revenue of BRL 862,248,000, operating profit prior to financial results of BRL 9,858,000, operating loss of BRL 5,868,000, net loss of BRL 4,603,000 or BRL 139 per batch of one thousand shares, cash used in operating activities of BRL 7,890,000, additions to fixed assets of BRL 3,734,000, additions to intangible assets of BRL 1,649,000 for the same quarter a year ago. For the year, on consolidated basis, the company reported net operating revenue of BRL 3,449,124,000, operating profit prior to financial results of BRL 4,176,000, operating loss of BRL 60,634,000, net loss of BRL 52,117,000 or BRL 1256 per batch of one thousand shares, cash used in operating activities of BRL 58,866,000, additions to fixed assets of BRL 22,025,000, additions to intangible assets of BRL 4,483,000 compared to the net operating revenue of BRL 3,470,310,000, operating profit prior to financial results of BRL 76,009,000, operating income of BRL 19,960,000, net income of BRL 20,353,000 or BRL 613 per batch of one thousand shares, cash used in operating activities of BRL 90,024,000, additions to fixed assets of BRL 6,648,000, additions to intangible assets of BRL 1,980,000 for the previous year. For the quarter, on parent basis, the company reported net operating revenue of BRL 837,904,000, operating loss prior to financial results of BRL 6,235,000, operating loss of BRL 24,646,000, net loss of BRL 20,156,000 or BRL -486 per batch of one thousand shares, cash used in operating activities of BRL 19,264,000, additions to fixed assets of BRL 4,943,000, additions to intangible assets of BRL 656,000 compared to the net operating revenue of BRL 750,888,000, operating profit prior to financial results of BRL 4,861,000, operating loss of BRL 6,838,000, net loss of BRL 4,603,000 or BRL -139 per batch of one thousand shares, cash used in operating activities of BRL 2,544,000, additions to fixed assets of BRL 1,247,000, additions to intangible assets of BRL 657,000 for the same quarter a year ago. For the year, on parent basis, the company reported net operating revenue of BRL 3,165,171,000, operating loss prior to financial results of BRL 15,034,000, operating loss of BRL 60,174,000, net loss of BRL 52,117,000 or BRL -1256 per batch of one thousand shares, cash used in operating activities of BRL 87,108,000, additions to fixed assets of BRL 8,279,000, additions to intangible assets of BRL 795,000 compared to the net operating revenue of BRL 3,085,103,000, operating profit prior to financial results of BRL 66,024,000, operating income of BRL 21,457,000, net income of BRL 20,353,000 or BRL 613 per batch of one thousand shares, cash used in operating activities of BRL 49,842,000, additions to fixed assets of BRL 3,855,000, additions to intangible assets of BRL 769,000 for the previous year.

Similar Private Companies By Industry

Company Name Region
Santa Casa de Misericórdia de Santo Amaro Americas
Labaclen Americas
Serma Serviços Médicos Assistenciais Ltda. Americas
Core Participações S.A. Americas
Saude Abc Servicos Medico Hospitalares Ltda Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Profarma Distribuidora de Produtos Farmacêuticos S.A., please visit www.profarma.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.